Eczema Drug's skin secrets under the microscope
NCT ID NCT05378698
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how the drug tralokinumab affects the skin of people with moderate to severe atopic dermatitis (eczema). Researchers measured drug levels and immune changes in skin samples after 16 weeks of treatment. The goal was to better understand how the drug works, which could help predict who will respond best. The study included 20 patients and 5 healthy volunteers, but it was terminated early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tralokinumab
What this could lead to
If successful, this could help doctors identify which patients with atopic dermatitis are most likely to benefit from tralokinumab.
What could go wrong
This small, early-phase study was terminated, so results may be limited. It focuses on understanding the drug's mechanism, not on proving it works for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich
Zurich, Canton of Zurich, 8091, Switzerland